3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
2
Phase 3
2
Phase 1/2
2
Status
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma, T-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
109
Cyclophosphamide
89
fludarabine
70
Carboplatin
57
Injections
56
Bevacizumab
49
Specimen Handling
43
Gemcitabine
41
Magnetic Resonance Spectroscopy
40
Paclitaxel
39
Nivolumab
38
venetoclax
36
Dexamethasone
35
Cisplatin
34
Biopsy
34
Temozolomide
31
Docetaxel
29
atezolizumab
27
Capecitabine
27
Oxaliplatin
26
Fluorouracil
26
Pemetrexed
24
Irinotecan
24
Azacitidine
24
abemaciclib
23
toripalimab
22
Fulvestrant
22
fludarabine phosphate
21
Rituximab
21
Leucovorin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
Solutions
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled